TESARO Announces Participation at Two Investor Conferences
Get Alerts TSRO Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Raymond James 38th Annual Institutional Investors Conference at the JW Marriott Grand Lakes in Orlando, Florida on Monday, March 6, 2017. Tim Pearson, EVP and CFO of TESARO, will present at 8:40 AM ET and participate in meetings with investors.
- The Barclays Global Healthcare Conference at the Loews Hotel in Miami, Florida on Wednesday, March 15, 2017. Lonnie Moulder, CEO of TESARO, will participate in an analyst-led moderated Q&A from 3:50 to 4:15 PM ET and in meetings with investors.
Live webcasts of the presentations at the Raymond James and Barclays conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESAROTESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]Source: TESARO, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics
- Provable Opens Early Access to Shield Swap, a Confidential Trading Venue Built for Compliance
- Beno Opens Luxury Waterfront Guest Lounge at Marsa Al Arab in Partnership with Jumeirah Group
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Raymond James, Barclays, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share